Dernières nouvelles pour Ridgetech (NASDAQ:RDGT) Stock

Ridgetech

Ridgetech Inc formerly China Jo-Jo Drugstores Inc is a retailer and distributor of pharmaceutical products. The company's operating segments include Retail drugstores, Online Pharmacy, and Drug wholesale. Retail drugstores segment sells prescription and over-the-counter medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy segment sells drugs through third-party platforms such as Alibaba's Tmall, JD.com, and Amazon.com. It generates maximum revenue from the Retail drugstores segment.

Ridgetech Inc

Citigroup analyst Kelsey Chia maintains Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Buy and raises the price target from $700 to $785.

News

Price Target

Analyst Ratings

MPWR

Citigroup Maintains Buy on Monolithic Power Systems, Raises Price Target to $785

Goldman Sachs analyst Christine Cho maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Buy and raises the price target from $310 to $390.

WING

Goldman Sachs Maintains Buy on Wingstop, Raises Price Target to $390

Goldman Sachs analyst Jason English maintains Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) with a Buy and raises the price target from $40 to $45.

Goldman Sachs Maintains Buy on Valvoline, Raises Price Target to $45

Goldman Sachs analyst Christine Cho maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Neutral and raises the price target from $184 to $205.

TXRH

Goldman Sachs Maintains Neutral on Texas Roadhouse, Raises Price Target to $205

Goldman Sachs analyst Christine Cho maintains Sweetgreen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) with a Neutral and lowers the price target from $23 to $15.

Goldman Sachs Maintains Neutral on Sweetgreen, Lowers Price Target to $15

Goldman Sachs analyst Christine Cho maintains Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Buy and raises the price target from $120 to $145.

SHAK

Goldman Sachs Maintains Buy on Shake Shack, Raises Price Target to $145

Sionna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SION#NASDAQ">SION</a>) released data from its Phase 1 trials of SION-719 and SION-451, the company&#8217;s first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">in healthy volunteers</a>.
One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45766701/sionna-therapeutics-announces-positive-phase-1-data-for-nbd1-stabilizers-sion-719-and-sion-451-and" rel="noreferrer noopener">the SION-451 trial</a>.
Data Highlights
Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna&#8217;s preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) model.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45730076/trevi-therapeutics-showcases-drug-that-cuts-cough-frequency-in-lung-disease-patients" rel="noreferrer noopener">Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients</a>
These data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators.
Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate.
One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451.
There were no TEAEs related to LFTs in SION-719-treated subjects.
The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state.
SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily.
Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators.
Next Steps For SION-719:
Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients.
Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026.
The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label.
The study will be completed before the Phase 2a trial is initiated.
Next Steps For SION-451:
Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109.
The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients.
Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026.
In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with&nbsp;approximately $219.2 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43607841/sionna-therapeutics-announces-closing-of-219-2-million-upsized-initial-public-offering-including-f" rel="noreferrer noopener">in gross proceeds</a>.
Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45770318/specialty-vehicles-propel-rev-group-in-q2-despite-rv-headwinds" target="_blank" rel="noreferrer noopener">Specialty Vehicles Propel REV Group In Q2 Despite RV Headwinds</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Biotech

Health Care

Movers

General

SION

Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial

Citigroup analyst Andrew Kaplowitz maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Buy and raises the price target from $327 to $371.

Citigroup Maintains Buy on Rockwell Automation, Raises Price Target to $371

Goldman Sachs analyst Atidrip Modak maintains Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Buy and raises the price target from $364 to $414.

Goldman Sachs Maintains Buy on Quanta Services, Raises Price Target to $414

eridianbet, the sports betting and iGaming division of Golden Matrix Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMGI#NASDAQ">GMGI</a>), a leading developer and licensor of B2B and B2C gaming platforms, today announced the signing of a two-year exclusive sponsorship agreement with the Aquatic Sports Association of Malta (ASA), the official governing body for water polo, swimming, and artistic swimming in Malta.
Under the terms of the agreement, Meridianbet becomes the exclusive betting partner of ASA, gaining integrated brand exposure across ASA events, digital platforms, and physical venues. The sponsorship includes the launch of the branded national cup competition - Meridianbet Super Cup, as well as LED road signage, scoreboard branding, and apparel sponsorships across Malta's aquatic sports federations.

GMGI

Golden Matrix Group's Meridianbet Signs 2-Yr Exclusive Sponsorship Agreement With Aquatic Sports Association Of Malta

Goldman Sachs analyst Noah Poponak maintains Parsons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) with a Buy and lowers the price target from $90 to $80.

Goldman Sachs Maintains Buy on Parsons, Lowers Price Target to $80

Goldman Sachs analyst Christine Cho maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Sell and lowers the price target from $24 to $19.

JACK

Goldman Sachs Maintains Sell on Jack In The Box, Lowers Price Target to $19

Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) reported better-than-expected first-quarter earnings and <a href="https://www.benzinga.com/quote/DG/earnings">raised its full-year outlook on Tuesday.</a>
The general store operator said quarterly net sales increased 5.3% to $10.44 billion, barely missing the consensus of $10.64 billion. The company reported net income of $391.9 million, up 7.9%, with earnings of $1.78 per share, compared to $1.65 a year ago, beating the consensus of $1.58.
&#8220;We are pleased with our start to the year, including strong same-store sales and EPS results,&#8221; said Todd Vasos, Dollar General&#8217;s chief executive officer. &#8220;Our efforts to improve execution and enhance the associate and customer experience are yielding positive outcomes in both our operational performance and our financial results. I want to thank our team for their hard work and dedication to serving our customers and communities with value and convenience every day. These efforts contributed to market share gains in sales of both consumables and non-consumables, and drove growth with both our core customer and trade-in customers during the quarter.&#8221;
The company is updating its expectations for the year, primarily to reflect its outperformance in the first quarter and the tariff uncertainty. The company now expects fiscal year 2025 sales growth of approximately 3.7% to 4.7%, compared to its previous expectation of approximately 3.4% to 4.4%.
Dollar General revised earnings guidance from $5.10-$5.80 per share to $5.20-$5.80 compared to the consensus of $5.62.
Dollar General shares fell 1% to $111.57 on Wednesday.
These analysts made changes to their price targets on Dollar General following earnings announcement.
<ul class="wp-block-list">
<li>Telsey Advisory Group analyst Joseph Feldman maintained Dollar General with a Market Perform and raised the price target from $100 to $120.</li>
<li>Barclays analyst Karen Short maintained the stock with an Overweight rating and raised the price target from $100 to $119.</li>
<li>B of A Securities analyst Robert Ohmes maintained Dollar General with a Buy and raised the price target from $115 to $135.</li>
<li>Wells Fargo analyst Edward Kelly maintained the stock with an Equal-Weight rating and raised the price target from $80 to $105.</li>
<li>UBS analyst Michael Lasser maintained Dollar General with a Buy and raised the price target from $120 to $128.</li>
<li>JP Morgan analyst Matthew Boss maintained the stock with a Neutral and raised the price target from $88 to $95.</li>
<li>Morgan Stanley analyst Simeon Gutman maintained Dollar General with an Equal-Weight rating and raised the price target from $85 to $115.</li>
<li>Truist Securities analyst Scot Ciccarelli maintained the stock with a Hold and raised the price target from $93 to $112.</li>
<li>Raymond James analyst Bobby Griffin maintained Dollar General with an Outperform rating and raised the price target from $100 to $125.</li>
<li>Citigroup analyst Paul Lejuez maintained the stock with a Neutral and raised the price target from $101 to $112.</li>
</ul>
Considering buying DG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DG/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04134406/image-54-1024x585.png" alt="" class="wp-image-938629" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04134406/image-54-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04134406/image-54-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04134406/image-54-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04134406/image-54.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45762621/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fal">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a></li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

These Analysts Increase Their Forecasts On Dollar General After Better-Than-Expected Q1 Earnings

Citigroup analyst Andrew Kaplowitz maintains Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) with a Buy and raises the price target from $242 to $265.

Citigroup Maintains Buy on Honeywell Intl, Raises Price Target to $265

Goldman Sachs analyst David Roman maintains HealthEquity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQY#NASDAQ">HQY</a>) with a Neutral and raises the price target from $94 to $104.

Goldman Sachs Maintains Neutral on HealthEquity, Raises Price Target to $104

Goldman Sachs analyst Adam Hotchkiss maintains Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) with a Buy and raises the price target from $235 to $270.

GWRE

Goldman Sachs Maintains Buy on Guidewire Software, Raises Price Target to $270

Goldman Sachs analyst Kate McShane maintains Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) with a Buy and raises the price target from $96 to $115.

Goldman Sachs Maintains Buy on Dollar General, Raises Price Target to $115

Citigroup analyst Andrew Kaplowitz maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Buy and raises the price target from $133 to $146.

Citigroup Maintains Buy on Emerson Electric, Raises Price Target to $146

B. Riley Securities analyst Naved Khan upgrades Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) from Neutral to Buy and raises the price target from $7 to $10.

Upgrades

YEXT

B. Riley Securities Upgrades Yext to Buy, Raises Price Target to $10

B. Riley Securities analyst Anna Glaessgen reiterates Sportsman's Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) with a Buy and raises the price target from $3 to $4.

Comments

Ridgetech

Actualités

Dernières nouvelles pour Ridgetech (NASDAQ:RDGT) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL